(Q30758170)

26 June 2017

title

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection (English)

1 reference

26 June 2017

Hélène Hardy

1

1 reference

26 June 2017

Paul R Skolnik

series ordinal

2

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

26 June 2017

1 reference

26 June 2017

volume

24

1 reference

26 June 2017

issue

2

1 reference

26 June 2017

page(s)

198-211

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

HIV fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

Predicting Diabetic Control from Competence, Adherence, Adjustment, and Psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.198.33141

10.1592/PHCO.24.2.198.33141

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference